224 related articles for article (PubMed ID: 16200942)
1. [Nonmyeloablative stem cell transplantation as cancer immunotherapy].
Willems E; Baron F; Vanstraelen G; Frère P; Fillet G; Beguin Y
Rev Med Suisse; 2005 Aug; 1(30):1973-7. PubMed ID: 16200942
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Minitransplants: allogeneic stem cell transplantation with reduced toxicity.
Beguin Y; Baron F
Acta Clin Belg; 2003; 58(1):37-45. PubMed ID: 12723260
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Baron F; Beguin Y
J Hematother Stem Cell Res; 2002 Apr; 11(2):243-63. PubMed ID: 11983097
[TBL] [Abstract][Full Text] [Related]
5. Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation: a clinical review.
Pollack SM; O'Connor TP; Hashash J; Tabbara IA
Am J Clin Oncol; 2009 Dec; 32(6):618-28. PubMed ID: 19593085
[TBL] [Abstract][Full Text] [Related]
6. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
7. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
8. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
Espinoza-Delgado I; Childs RW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
[TBL] [Abstract][Full Text] [Related]
9. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].
Cheng YC; Ueno NT
Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma.
Childs RW
Crit Rev Immunol; 2001; 21(1-3):191-203. PubMed ID: 11642604
[TBL] [Abstract][Full Text] [Related]
11. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
[TBL] [Abstract][Full Text] [Related]
12. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
Rizzieri DA; Koh LP; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Smith C; Gong JZ; Lagoo A; Niedzwiecki D; Dowell JM; Waters-Pick B; Liu C; Marshall D; Vredenburgh JJ; Gockerman J; Decastro C; Moore J; Chao NJ
J Clin Oncol; 2007 Feb; 25(6):690-7. PubMed ID: 17228020
[TBL] [Abstract][Full Text] [Related]
13. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
14. Pain syndromes in the setting of haematopoietic stem cell transplantation for haematological malignancies.
Niscola P; Romani C; Scaramucci L; Dentamaro T; Cupelli L; Tendas A; Piccioni D; Giovannini M; Tolu B; Cartoni C; Arcuri E; Perrotti A; Palumbo R; de Fabritiis P
Bone Marrow Transplant; 2008 May; 41(9):757-64. PubMed ID: 18246112
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
[TBL] [Abstract][Full Text] [Related]
16. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience.
Shimoni A; Nagler A
Curr Hematol Rep; 2004 Jul; 3(4):242-8. PubMed ID: 15217553
[TBL] [Abstract][Full Text] [Related]
17. Can reduced-intensity allogeneic transplantation cure older adults with AML?
Storb R
Best Pract Res Clin Haematol; 2007 Mar; 20(1):85-90. PubMed ID: 17336258
[TBL] [Abstract][Full Text] [Related]
18. Future strategies in hematopoietic stem cell transplantation for rheumatoid arthritis.
Burt RK; Barr W; Oyama Y; Traynor A; Slavin S
J Rheumatol Suppl; 2001 Oct; 64():42-8. PubMed ID: 11642504
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation in the elderly.
Shapira MY; Tsirigotis P; Resnick IB; Or R; Abdul-Hai A; Slavin S
Crit Rev Oncol Hematol; 2007 Oct; 64(1):49-63. PubMed ID: 17303434
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
